Ascentage Pharma Partially Exercises ADS Over-Allotment Option
Ticker: AAPG · Form: 6-K · Filed: Feb 11, 2025 · CIK: 2023311
Sentiment: neutral
Topics: offering, ADS, option exercise
TL;DR
Ascentage Pharma partially exercised its ADS over-allotment option on Feb 7, 2025.
AI Summary
Ascentage Pharma Group International announced on February 7, 2025, the partial exercise of the over-allotment option for its American Depositary Shares (ADS) offering. This action relates to the company's offering of ADSs, details of which were provided in a Hong Kong Stock Exchange announcement and a press release.
Why It Matters
This filing indicates a partial exercise of an over-allotment option, which can impact the final number of shares issued and potentially the stock's trading dynamics.
Risk Assessment
Risk Level: low — This is a routine filing related to the exercise of an over-allotment option from a previous offering, not indicating new significant risks.
Key Players & Entities
- Ascentage Pharma Group International (company) — Registrant
- February 7, 2025 (date) — Date of announcement
- American Depositary Shares (security) — Subject of the offering and option exercise
FAQ
What was announced on February 7, 2025, by Ascentage Pharma Group International?
Ascentage Pharma Group International announced the partial exercise of the over-allotment option in relation to the offering of American Depositary Shares.
Where was the announcement regarding the over-allotment option made?
The announcement was made via a Hong Kong Stock Exchange announcement and a press release.
What is the filing form type?
The filing form type is a 6-K.
What is the Commission File Number for Ascentage Pharma Group International?
The Commission File Number is 002-023311.
What is the principal executive office address of Ascentage Pharma Group International?
The principal executive office is located at 68 Xinqing Road, Suzhou Industrial Park, Suzhou, Jiangsu, China.
Filing Stats: 257 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2025-02-10 21:45:45
Filing Documents
- f6k_021025.htm (6-K) — 14KB
- exh_991.htm (EX-99.1) — 10KB
- exh_992.htm (EX-99.2) — 6KB
- logo.jpg (GRAPHIC) — 8KB
- 0001171843-25-000725.txt ( ) — 42KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________________________ FORM 6-K ______________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 002-023311 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) ______________________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F On February 7, 2025, Ascentage Pharma Group International issued (1) a Hong Kong Stock Exchange announcement entitled “PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION IN RELATION TO THE OFFERING OF AMERICAN DEPOSITARY SHARES”; and (2) a press release entitled “Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares”. A copy of the Hong Kong Stock Exchange announcement is attached as Exhibit 99.1 to this Form 6-K and a copy of the press release is attached as Exhibit 99.2 to this Form 6-K and each is incorporated by reference herein. INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Hong Kong Stock Exchange Announcement dated February 7, 2025 99.2 Press Release, dated February 7, 2025. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: February 10, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer